While some studies reported higher rates of post-stroke epilepsy in patients undergoing thrombolytic therapy with intravenous tPA [190,191], this could be due to the factors associated with the treatment protocol and the inclusion of patients with more severe ischemic damage resulting in higher seizure incidence, rather than the epileptogenic properties of exogenous tPA [191]. This evidence concerns the gene PLAT and stroke disorder.